Thus, an immunohistochemistry targeting SOX10 and ANKRD55 discriminates between CNS_NBL and other malignant pediatric CNS neoplasms (sensitivity—100% and specificity 98% for CNS_NBL). This evidence concerns the gene SOX10 and central nervous system neoplasm.